Icon

GILOTRIF (nda201292)- (EQ 20MG BASE,EQ 30MG BASE,EQ 40MG BASE)

AFATINIB DIMALEATE BOEHRINGER INGELHEIM
EQ 20MG BASE,EQ 30MG BASE,EQ 40MG BASE
Yes No
2031-Jan-05 2018-Jul-12
2020-Jul-12 None
None No
GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
0 3 0
Total Other Developers None
Drugs with Suitability No
EQ 20MG BASE ** ** - - -
EQ 30MG BASE ** ** - - -
EQ 40MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.